US Pharma MarketingBeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'
The FDA has issued an untitled letter to BeOne Medicines’ U.S. The FDA has issued an untitled letter to BeOne Medicines’ U.S. subsidiary over a TV commercial promoting its BTK blood cancer drug Brukinsa, saying the ad used “compelling and attention-grabbing visuals” that did not hold up to scrutiny.
The FDA has issued an untitled letter to BeOne Medicines’ U.S. subsidiary over a TV commercial promoting its BTK blood cancer drug Brukinsa, saying the ad used “compelling and attention-grabbing visuals” that did not hold up to scrutiny.
Source: FiercePharma